Waters Corp. Updates Instruments and Software - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters Corp. Updates Instruments and Software


At Pittcon 2013 in Philadelphia, Waters Corp. announced improvement to chromatography systems and software.

The company reported enhancements to the Waters Alliance HPLC system that will maintain key Alliance performance specifications and control algorithms to ensure that analysts can replicate their existing methods. The system features updated electronics and user interface. The updated systems can be used with Waters eXtended Performance [XP], 2.5 μm columns.

The company also announced an expansion of its laboratory informatics offerings, with the addition of Paradigm Scientific Search Software, which allows users to perform object-based searches across both structured and unstructured data and across different data platforms.

Mobile access and new laboratory analytics enhancements were added to Empower 3 chromatography data software.

Quality Control Reference Materials (QCRMs) and Certified Containers for Waters instruments were added to the Analytical Standards and Reagents product group.

Another technology introduction is the Waters ACQUITY Advanced Polymer Chromatography (APC) System, the company says, defines a new category of chromatographic polymer analysis, yielding improved molecular weight information about polymeric species, faster than ever before.

Waters Corp. announced updates to the Alliance HPLC system and Empower 3 chromatography data software, and introduced search software and reference materials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here